文献速递生殖医学母胎医学

辅助生殖技术后新鲜或冷冻胚胎移植妊娠中游离DNA的胎儿分数

Fetal fraction of cell-free DNA in pregnancies after fresh or frozen embryo transfer following assisted reproductive technologies.
PubMed 文献 · Hum Reprod · 2020-01-01

该病例对照研究比较了辅助生殖技术(ART)治疗后妊娠与自然受孕妊娠的游离DNA胎儿分数(FF)。结果显示ART患者FF显著降低,新鲜胚胎移植后降低更明显(平均FF=0.049)较冷冻胚胎移植(平均FF=0.063),多因素分析校正母体BMI后P=0.02。

要点

  • ART妊娠较自然受孕FF显著降低(平均FF=0.056 vs 0.072,P<0.0001)。
  • 新鲜胚胎移植后FF降低较冷冻胚胎移植更明显(0.049 vs 0.063,P=0.02)。
  • 母体BMI增加及PAPP-A MoM值降低与FF显著降低相关。

核心结论

  • ART妊娠较自然受孕FF显著降低,且新鲜胚胎移植后降低较冷冻胚胎移植更明显,可能反映新鲜胚胎移植后小于胎龄儿的倾向。

研究设计与样本

  • 病例对照研究,纳入54例ART治疗后持续妊娠妇女,排除后统计分析基于新鲜胚胎移植23例和改良自然周期冻融胚胎移植26例的NIPT样本,纳入时间为2018年2月至2018年11月,对照组为238例自然受孕且早孕期联合筛查高风险妊娠。

主要发现

  • ART妊娠平均FF=0.056,自然受孕平均FF=0.072,校正BMI和PAPP-A MoM值后P<0.0001。
  • 新鲜胚胎移植平均FF=0.049,冷冻胚胎移植平均FF=0.063,校正母体BMI后P=0.02。
  • 母体BMI增加与FF显著降低相关(P<0.0001)。
  • PAPP-A MoM值降低与FF显著降低相关(P=0.003)。

局限性

  • 研究设计局限性为样本量相对较小。
  • 对照组未与ART治疗妇女匹配。
  • 对照组多数妇女因cFTS高风险而生化标志物存在差异,但ART治疗妇女新鲜或冷冻胚胎移植亚组内生化标志物无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is the fetal fraction (FF) of circulating cell-free DNA (cfDNA) affected in pregnancies following ART treatment with either fresh or frozen embryo transfer (ET) compared with natural conception? SUMMARY ANSWER: This study shows a significant reduction in the FF in ART patients compared with naturally conceived pregnancies, which seems to be more pronounced after fresh ET compared with frozen ET. WHAT IS KNOWN ALREADY: Non-invasive prenatal testing (NIPT) is based on cfDNA in maternal blood, of which about 10% is of placental origin and thus represents the fetal karyotype. Validation studies have demonstrated a high sensitivity, specificity and positive predictive value of NIPT for the detection of fetal trisomy 21, 18 and 13. Nevertheless, the FF of cfDNA is an important factor for NIPT test accuracy. Several studies have found a reduction in FF for pregnancies following ART in comparison with natural conception. However, knowledge on how the FF is affected in ART pregnancies after fresh ET compared with frozen ET is very limited. STUDY DESIGN, SIZE, DURATION: The study was designed as a case-control study. A total of 54 women with an ongoing pregnancy following ART treatment were included. After exclusion for different reasons, statistical analyses were based on 23 NIPT samples from pregnant women treated with fresh ET and 26 NIPT samples from pregnant women treated with frozen-thawed ET in a modified natural cycle. Women were included between February 2018 and November 2018. The results were compared with a control group of 238 naturally conceived pregnancies with a high-risk result from the combined first trimester screening (cFTS). PARTICIPANTS/MATERIALS, SETTING, METHODS: The study included women from the Fertility Clinics at Copenhagen University Hospital Hvidovre and Copenhagen University Hospital Rigshospitalet. Blood samples for NIPT analysis were drawn between 11 + 0 and 14 + 2 weeks of gestation and were all analyzed at the NIPT Center at Copenhagen University Hospital Hvidovre. The NIPT-test was performed by massive-parallel whole-genome sequencing. The FF was determined using the SeqFF algorithm. MAIN RESULTS AND THE ROLE OF CHANCE: We found a reduction in FF in ART patients compared with naturally conceived pregnancies, and the reduction was more pronounced for ART pregnancies after fresh ET (mean FF = 0.049) compared with frozen ET (mean FF = 0.063) (multivariate analysis adjusted for maternal BMI, P = 0.02). Another multivariate analysis, adjusted for BMI and multiples of median (MoM) values for pregnancy-associated plasma protein-A (PAPP-A), demonstrated a significantly reduced FF for ART pregnancies (mean FF = 0.056) compared with naturally conceived pregnancies (mean FF = 0.072) (P < 0.0001). We found that FF was significantly reduced with increasing maternal BMI (P < 0.0001) and with decreasing MoM values of PAPP-A (P = 0.003). LIMITATIONS, REASONS FOR CAUTION: A limitation of our study design was the relatively small sample size. Another limitation was that the control group was not matched with the ART-treated women. The majority of the women from the control group had a high risk from cFTS, thereby their biochemical markers were diverging. However, the biochemical markers for the ART-treated women with fresh or frozen ET were not divergent within the subgroups. WIDER IMPLICATIONS OF THE FINDINGS: Concurrent with other studies demonstrating a reduced FF for singleton pregnancies after ART treatment compared with naturally conceived pregnancies, we found a reduction in FF between the two groups. This is one of the first studies to examine FF in ART pregnancies after fresh ET compared with frozen ET, hence the existing knowledge is limited. We find that FF is even more reduced in pregnancies following fresh ET compared with frozen ET, which might possibly reflect the predisposition of being small for gestational age after fresh ET compared with natural cycle frozen ET. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by the A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal (the A.P. Møller Foundation for General Purposes). All authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: NA.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Talbot AL, Ambye L, Hartwig TS, et al. Fetal fraction of cell-free DNA in pregnancies after fresh or frozen embryo transfer following assisted reproductive technologies. Hum Reprod. 2020. PMID: 32539141. doi:10.1093/humrep/deaa110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。